The maker of a promising ovarian cancer drug said, Friday, that he stopped enrolling women in a study because several patients developed gastrointestinal holes.
At least seven patients developed gastrointestinal holes.
( z1 develop :ARG0 ( z2 patient :quant ( z3 at-least :op 7 ) ) :ARG1 ( z4 hole :mod ( z5 gut ) ) )